MedTrace Logo

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 742

Last updated 2012-08-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Talactoferrin

Oral, 1.5 grams twice per day

DRUG

Placebo

Oral, twice per day

Sponsors & Collaborators

  • Agennix

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-03-31
Completion
2012-08-31

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Italy
  • Latvia
  • Malaysia
  • Philippines
  • Poland
  • Romania
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00707304 on ClinicalTrials.gov